Explaining Unapproved Drugs to Payors: FDA Guidance Helps Pharma Avoid Pitfalls

Explaining Unapproved Drugs to Payors: FDA Guidance Helps Pharma Avoid Pitfalls

The FDA has issued new guidance on how drug manufacturers can communicate information about unapproved drugs to payors, aiming to reduce legal risks. This article explains the key provisions, including what can and cannot be said about study results, and offers strategic insights for pharma teams. For business development teams, investors, and analysts watching the regulatory landscape, the document clarifies a historically gray area: how to discuss unapproved uses and investigational products with formulary committees without triggering off-label promotion enforcement.

Key Takeaways

• The FDA's new guidance clarifies how pharma can communicate about unapproved drugs to payors without violating off-label promotion rules. Companies may share study results with payors but cannot claim superiority or label the drug as "drug of choice."
• The guidance applies to both drugs and devices, impacting formulary committee discussions and health care economic information (HCEI) communications under the Food and Drug Administration Modernization Act of 1997 (FDAMA 114).
• For BD teams and analysts, this reduces legal uncertainty around pre-approval payor engagement but preserves key restrictions on comparative claims, which will shape competitive positioning strategies in crowded therapeutic areas.

What the FDA's New Payor Communications Guidance Actually Says

The agency released a guidance document titled "Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers", which provides answers to common questions concerning firms' communication of health care economic information regarding their prescription drugs. Under the guidance, companies would be allowed to explain any study results to payors but not to characterize the candidate as showing superior efficacy over other treatments or as the "drug of choice" for an indication. This addresses the long-standing challenge of discussing unapproved uses without crossing into illegal off-label promotion — a tension that has dogged pharma commercial teams for decades.

The distinction matters because, under baseline FDA regulations, physicians may prescribe drugs for off-label use, but drug manufacturers may not promote such uses, as noted in the peer-reviewed literature on off-label drug regulation. The new guidance does not change that fundamental prohibition; it simply creates a safe harbor for factual, non-promotional discussions with sophisticated payor audiences who need data to make formulary decisions.

Unapproved prescription drugs pose significant risks to patients because they have not been reviewed by FDA for safety, effectiveness or quality, per the agency's Unapproved Drugs initiative page. That initiative, announced in June 2006, has removed roughly 14 categories of drugs from the market as of October 2011, though it has been controversial due to resulting price increases for some previously unapproved products.

How This Changes the Calculus for Pharma Commercial Teams

For BD teams, investors, and analysts, this guidance reduces legal uncertainty around payor communications for drugs that are not yet fully approved or are being studied for new indications. Companies can now more confidently engage payors early, potentially accelerating formulary access and market uptake. However, the prohibition on superiority claims means that comparative effectiveness data must be presented neutrally. This may affect competitive positioning strategies, especially for drugs entering crowded therapeutic areas such as oncology, immunology, or metabolic disease.

The practical implication is significant: a manufacturer developing a candidate that matches an existing standard of care on efficacy but offers a better safety profile cannot tell a payor that the drug is "superior" until the FDA has signed off on that specific claim. Instead, the conversation must stick to the raw data — here are the progression-free survival curves, here are the adverse event rates — and let the payor draw its own conclusions. Teams should update their compliance protocols and training to align with the guidance, and monitor FDA enforcement actions for any shifts in interpretation.

The guidance also applies to devices, expanding the scope of affected stakeholders. Formulary committees for hospital systems, pharmacy benefit managers, and Medicare Part D plans all fall within the intended audience, meaning the guidance touches nearly every channel through which products reach patients in the US.

What Kinds of Drugs Fall Into the Unapproved Category?

The FDA's Unapproved Drugs Initiative targets prescription drugs that have never undergone the agency's review process. Examples of drugs that historically were marketed without approval include colchicine (used for gout), nitroglycerin, morphine, phenazopyridine, phenobarbital, potassium chloride, and sodium fluoride. Many of these have since been brought under the regulatory umbrella through the FDA's enforcement efforts, but the category remains relevant because manufacturers continue to develop reformulations, new delivery systems, and combination products that may start as unapproved entities in the eyes of payors.

For companies bringing a previously unapproved drug through the 505(b)(2) or 505(b)(1) pathway, the guidance offers a roadmap for early payor discussions that can reduce the time between approval and formulary placement. That time-to-access window is a critical metric for investors evaluating late-stage pipeline assets.

Frequently Asked Questions

What to Watch Next

The FDA's guidance is final, but its enforcement posture will determine whether the safe harbor is meaningful or illusory. Companies should pay attention to any Warning Letters or Untitled Letters that cite communications with payors as off-label promotion — those enforcement actions will draw the real boundary lines around permissible speech. For analysts tracking the regulatory risk profile of specific assets, the guidance is a modest positive: it reduces one category of legal uncertainty without eliminating it entirely. BD teams evaluating in-licensing opportunities should ask target companies whether their payor communication protocols have been updated to reflect the new framework, as legacy practices may carry residual risk.

The document also signals that the FDA is willing to create carve-outs for sophisticated audiences like formulary committees, even as it maintains the general prohibition on manufacturer promotion of unapproved uses. That trend could extend to other contexts — such as communications with integrated delivery networks or accountable care organizations — and bears watching by anyone with a stake in pharmaceutical commercialization strategy.

Related coverage

• FDA Cyber Guidance: New Priorities for Medical Device Companies
• Opinion: The Amish Way of Healthcare Offers Lessons for Public Health
• FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development